<DOC>
	<DOCNO>NCT02495922</DOCNO>
	<brief_summary>Trial patient newly diagnose myeloma evaluate effect elotuzumab induction consolidation therapy bortezomib/lenalidomide/dexamethasone lenalidomide maintenance treatment</brief_summary>
	<brief_title>A Phase III Trial Effect Elotuzumab VRD Induction /Consolidation Lenalidomide Maintenance Patients With Newly Diagnosed Myeloma</brief_title>
	<detailed_description>Prospective , multicentre , randomise , parallel group , open , phase III clinical trial , patient confirm diagnosis untreated multiple myeloma require systemic therapy . Investigational Medicinal Products : Elotuzumab , lenalidomide Patients randomize one 4 study arm ( A1 , A2 , B1 , B2 ) . Patients randomized arm A1 A2 receive 4 cycle VRD ( Bortezomib ( Velcade® ) , Lenalidomide ( Revlimid® ) , Dexamethasone ) . Patients arm B1 B2 additionally receive monoclonal antibody Elotuzumab 4 cycle VRD . After induction therapy patient undergo intensify therapy accord GMMG standard ( usually mobilization therapy follow stem cell collection autologous stem cell transplantation ) . After intensification consolidation therapy perform two cycle VRD ( A1 und B1 ) VRD+ Elotuzumab ( A2 und B2 ) , follow Lenalidomide maintenance therapy ( arm A2 B2 ) without ( arm A1 B1 ) additional Elotuzumab . Maintenance therapy perform 2 year . Primary objective determination best four treatment strategy regard progression-free survival ( PFS ) , define time randomisation progression death cause whichever occur first . The duration trial patient expect 36-39 month ( induction intensification treatment : 7-10 month , 3 month rest intensification start consolidation , consolidation 2 month , maintenance phase 24 month ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients meet follow criterion consider admission trial : Confirmed diagnosis untreated multiple myeloma require systemic therapy ( diagnostic criterion ( IMWG update criterion ( 2014 ) ) Measurable disease , define quantifiable monoclonal protein value , define least one follow three measurement : Serum Mprotein ≥ 10g/l ( IgA ≥ 5g/l ) Urine lightchain ( Mprotein ) ≥ 200 mg/24 hour Serum FLC assay : involve FLC level ≥ 10 mg/dl provide sFLC ratio abnormal Age 18 70 year inclusive WHO performance status 03 ( WHO=3 allow cause MM comorbid condition ) Negative pregnancy test inclusion ( woman childbearing potential ) For men woman childbearing potential : patient must willing capable use adequate contraception complete therapy . Patients must agree requirement regard lenalidomide pregnancy prevention programme describe chapter 6 . All patient must agree abstain donate blood take lenalidomide 28 day follow discontinuation lenalidomide therapy agree share study drug lenalidomide another person return unused study drug investigator pharmacist Ability patient understand character individual consequence clinical trial Written inform consent ( must available enrollment trial ) Patients present follow criterion include trial : Patient know hypersensitivity drug give protocol , notably bortezomib , lenalidomide , dexamethasone elotuzumab constituent compound ( incl . boron mannitol ) . Systemic AL amyloidosis ( except AL amyloidosis skin bone marrow ) Previous chemotherapy radiotherapy past 5 year except local radiotherapy case local myeloma progression . Severe cardiac dysfunction ( NYHA classification IIIIV ) Significant hepatic dysfunction ( serum bilirubin ≥ 1,8mg/dl and/or ASAT and/or ALAT ≥ 2.5 time normal level ) , unless relate myeloma . Patients renal insufficiency require hemodialysis HIV positivity Patients active history hepatitis B C Patients active , uncontrolled infection Patients peripheral neuropathy neuropathic pain , CTC grade 2 high ( define NCI Common Terminology Criteria Adverse Events ( NCI CTCAE ) Version 4.0 ) Patients history active malignancy past 5 year exception basal cell carcinoma skin stage 0 cervical carcinoma treat curative intent Patients acute diffuse infiltrative pulmonary and/or pericardial disease Autoimmune hemolytic anemia positive Coombs test immune thrombocytopenia Platelet count &lt; 75 x 109/l , , dependent bone marrow infiltration plasma cell , platelet count &lt; 30 x 109/l ( patient platelet count &lt; 75 x 109/l , &gt; 30 x 109/l may eligible percentage plasma cell bone marrow ≥ 50 % ) , ( transfusion support within 14 day test allow ) Haemoglobin ≤ 8.0 g/dl , unless relate myeloma Absolute neutrophil count ( ANC ) &lt; 1.0 x 10^9/l ( use colony stimulate factor within 14 day test allow ) , unless relate myeloma Pregnancy lactation Participation clinical trial . This include longterm followup period without active drug treatment previous study last 6 month . No patient allow enrol trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>